Are there unique genetic markers for ADHD in females?

PostedOctober 8, 2025

UpdatedOctober 10, 2025

ByMy Patient Advice

Author: Victoria Rowe, MSc | Reviewed by: Dr. Rebecca Fernandez, MBBS

Yes, female ADHD genetic markers are an area of increasing interest in ADHD research, as studies reveal that the genetic factors influencing ADHD in females may differ from those in males. While ADHD is more commonly diagnosed in boys, underdiagnosis in females is frequent due to differing symptom profiles, which are often more subtle or internalising. Recent research is uncovering gene variants that may be more prevalent or uniquely expressed in females, offering new insights into ADHD’s clinical profiles and contributing to more accurate diagnoses.

How ADHD Genetic Markers Differ in Females

This often shows variations linked to emotional regulation and executive function, contributing to underdiagnosis and differing symptom expression.

Gender-specific gene variants

Studies suggest that females with ADHD may have specific genetic markers that influence the presentation of symptoms, which can differ from those seen in males. For instance, dopamine-related genes like DRD4 (dopamine receptor) and COMT (catechol-O-methyltransferase) are linked to ADHD, but research indicates that these variants may express differently in females. Females with certain DRD4 variants may show more inattention and emotional regulation issues, while males with the same variant may display higher levels of hyperactivity and impulsivity.

Subtle symptom expression

Females with ADHD often experience a different symptom profile compared to males, with more internalising behaviours (e.g., anxiety or depression) and fewer externalising behaviours (e.g., hyperactivity). This difference may be linked to genetic markers that influence how the brain develops, especially in areas related to emotional regulation, working memory, and attention. These subtle differences often contribute to the underdiagnosis of ADHD in females, as the symptoms may not be immediately recognised as ADHD-related.

Why Female ADHD Genetic Markers Matter

Improved diagnosis

Identifying female ADHD genetic markers could lead to more accurate diagnoses. Females often present with symptoms that are overlooked or misinterpreted as anxiety, mood disorders, or even personality issues. Understanding the genetic underpinnings that contribute to this distinct symptom presentation could help clinicians recognise ADHD earlier in females.

Personalised treatment strategies

Understanding how genetic variants influence ADHD symptoms in females can help develop personalised treatments. Medications and therapies targeting specific brain pathways, such as dopamine regulation, might be tailored to females based on their genetic profiles, improving effectiveness and reducing side effects.

Addressing gender differences in clinical profiles

Research into female ADHD genetic markers helps highlight the importance of considering gender when assessing ADHD. Gender-specific markers could lead to treatments that are better aligned with females’ needs, ensuring that both males and females receive the appropriate care for their unique ADHD symptoms.

There is growing recognition that female ADHD genetic markers are key to understanding how ADHD manifests differently in females. By identifying and studying these markers, we can improve diagnosis, treatment, and ultimately, the quality of life for females with ADHD.

Visit providers like ADHD Certify for personal consultations that explore genetic markers and their impact on ADHD treatment.

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Genetic studies and biomarkers.

Victoria Rowe, MSc

Author

Victoria Rowe is a health psychologist with a Master’s in Health Psychology and a BS in Applied Psychology. She has experience as a school psychologist, conducting behavioural assessments, developing individualized education plans (IEPs), and supporting children’s mental health. Dr. Rowe has contributed to peer-reviewed research on mental health, including studies on anxiety disorders and the impact of COVID-19 on healthcare systems. Skilled in SPSS, Minitab, and academic writing, she is committed to advancing psychological knowledge and promoting well-being through evidence-based practice.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Rebecca Fernandez, MBBS

Reviewer

Dr. Rebecca Fernandez is a UK-trained physician with an MBBS and experience in general surgery, cardiology, internal medicine, gynecology, intensive care, and emergency medicine. She has managed critically ill patients, stabilised acute trauma cases, and provided comprehensive inpatient and outpatient care. In psychiatry, Dr. Fernandez has worked with psychotic, mood, anxiety, and substance use disorders, applying evidence-based approaches such as CBT, ACT, and mindfulness-based therapies. Her skills span patient assessment, treatment planning, and the integration of digital health solutions to support mental well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewer's privacy.